EU bans marketing of around 700 generic medicines of GVK Biosciences
European Union (EU) has banned the marketing of around 700 generic medicines among its member countries.
This is the largest suspension imposed on the sales and distribution of generic drugs ordered by EU which will come into effect on August 21, 2015 and it will be applicable to all 28 member nations.
These generic medicines were banned after it was found that the clinical trials conducted by Hyderabad-based pharmaceutical research company GVK Biosciences were manipulated.
European commission had taken decision in this regard in response to a recommendation given by the EU’s nodal drug regulator European Medicines Agency (EMA) in January 2015. In its recommendations EMA had mentioned that the marketing authorisations of these drugs were based on clinical trial data which was allegedly manipulated by the Indian company.
With this ban, medicines 700 generic medicines will lose their validity for use in the EU from and no longer they will be distributed or sold by pharmaceutical companies, drugs stores wholesale dealers and other outlets.